Avas Pharmaceuticals has launched Lupin’s NaMuscla for the treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Italy. The drug, initially commercialised as a Class C (Tier 2), is undergoing reimbursement negotiations with AIFA (Agenzia Italiana del Farmaco). Read more: https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/avas-launches-lupins-rare-disease-drug-in-italy/117634058